<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide is an effective drug in low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with isolated del(5q), although not <z:hpo ids='HP_0000001'>all</z:hpo> patients respond </plain></SENT>
<SENT sid="1" pm="."><plain>Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome </plain></SENT>
<SENT sid="2" pm="."><plain>In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, conventional G-banding cytogenetics (CC), single nucleotide polymorphism array (SNP-A), and genomic sequencing methods were used </plain></SENT>
<SENT sid="3" pm="."><plain>SNP-A analysis (with control sample, lymphocytes CD3+, in 30 cases) revealed 5q losses in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="4" pm="."><plain>Other recurrent abnormalities were infrequent and were not associated with lenalidomide responsiveness </plain></SENT>
<SENT sid="5" pm="."><plain>Low karyotype complexity (by CC) and a high baseline platelet count (&gt;280 × 10(9) /l) were associated with the achievement of haematological response (P = 0·020, P = 0·013 respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>Unmutated TP53 status showed a tendency for haematological response (P = 0·061) </plain></SENT>
<SENT sid="7" pm="."><plain>Complete cytogenetic response was not observed in any of the mutated TP53 cases </plain></SENT>
<SENT sid="8" pm="."><plain>By multivariate analysis, the most important predictor for lenalidomide treatment failure was a platelet count &lt;280 × 10(9) /l (Odds Ratio = 6·17, P = 0·040) </plain></SENT>
<SENT sid="9" pm="."><plain>This study reveals the importance of a low baseline platelet count, karyotypic complexity and TP53 mutational status for response to lenalidomide treatment </plain></SENT>
<SENT sid="10" pm="."><plain>It supports the molecular study of TP53 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients treated with lenalidomide </plain></SENT>
</text></document>